BRETYLIUM TOSYLATE

Bretylium tosylate is an antiarrhythmic agent that blocks norepinephrine release and prolongs cardiac action potential. It is reserved for life‑threatening ventricular arrhythmias. Side effects include hypotension, nausea, and dizziness.

SKU: c1c2a507c5c6 Category: Tag:

Product Description


Mechanism of action

Bretylium is an adrenergic neuronal‑blocking agent that initially releases norepinephrine from presynaptic terminals, followed by long‑lasting inhibition of catecholamine release. In cardiac tissue it prolongs action potential duration by blocking potassium channels, giving it class III antiarrhythmic properties.

Benefits and advantages

Used in electrophysiology research, arrhythmia models, sympathetic‑nerve function studies, potassium‑channel analysis and investigation of neuronal‑blocking mechanisms.

Side effects and risks

Risks include profound hypotension, dizziness, arrhythmias, GI upset and sympathetic blockade. Handle with cardiovascular‑active compound precautions.

Datasheet


Molecular Formula

C18H24BrNO3S

Molecular Weight

414.4 g/mol

CAS Number

61-75-6

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

>62.2 [ug/mL] (The mean of the results at pH 7.4)

Purity

Purity information is available upon request (COA).

Synonym

Bretylium tosylate; 61-75-6; Bretylol; Bretylium tosilate; Darentin

IUPAC/Chemical Name

(2-bromophenyl)methyl-ethyl-dimethylazanium;4-methylbenzenesulfonate

InChl Key

KVWNWTZZBKCOPM-UHFFFAOYSA-M

InChl Code

InChI=1S/C11H17BrN.C7H8O3S/c1-4-13(2,3)9-10-7-5-6-8-11(10)12;1-6-2-4-7(5-3-6)11(8,9)10/h5-8H,4,9H2,1-3H3;2-5H,1H3,(H,8,9,10)/q+1;/p-1

References

https://pubchem.ncbi.nlm.nih.gov/compound/6100;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download